CYP3A4-mediated oxygenation versus dehydrogenation of raloxifene

Biochemistry

Volumn 49, Issue 21, 2010, Pages 4466-4475

  Moore, Chad D ^a   Reilly, Christopher A ^a   Yost, Garold S ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARENE OXIDES; BREAST CANCER; CHEMOPREVENTION; CYTOCHROME P450-3A4; NOVEL ROUTE; POSTMENOPAUSAL WOMEN; REACTIVE INTERMEDIATE; TAMOXIFEN;

CARBOXYLIC ACIDS; ESTERS; ORGANIC ACIDS; OXYGENATION; OXYGENATORS;

DEHYDROGENATION;

3' HYDROXYRALOXIFENE; 7 HYDROXYRALOXIFENE; CARBOXYLIC ACID; CYTOCHROME P450 3A4; DRUG METABOLITE; OXYGEN 18; RALOXIFENE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEHYDROGENATION; DRUG CONJUGATION; DRUG METABOLISM; DRUG STRUCTURE; HYDROLYSIS; METABOLITE; MOLECULAR DYNAMICS; OXYGENATION; PRIORITY JOURNAL;

APOPROTEINS; BREAST NEOPLASMS; CHEMOPREVENTION; CYTOCHROME P-450 CYP3A; DNA DAMAGE; FEMALE; HUMANS; RALOXIFENE; TAMOXIFEN;

EID: 77952806659     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi902213r     Document Type: Article

References (36)

1. Horner, M. J., Ries, L. A. G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N., Altekruse, S. F., Feuer, E. J., Huang, L., Mariotto, A., Miller, B. A., Lewis, D. R., Eisner, M. P., Stinchcomb, D. G., and Edwards, B. K. (2009) SEER Cancer Statistics Review, 1975?2006, National Cancer Institute, Bethesda, MD.
2. Osborne, C. K. (1998) Tamoxifen in the treatment of breast cancer N. Engl. J. Med. 339, 1609-1618
3. Hortobagyi, G. N. (1998) Treatment of breast cancer N. Engl. J. Med. 339, 974-984
4. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90, 1371-1388
5. Magriples, U., Naftolin, F., Schwartz, P. E., and Carcangiu, M. L. (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients J. Clin. Oncol. 11, 485-490
6. Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., and Cronin, W. M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86, 527-537 (Pubitemid 24111008)
7. Curtis, R. E., Boice, J. D., Jr., Shriner, D. A., Hankey, B. F., and Fraumeni, J. F., Jr. (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer J. Natl. Cancer Inst. 88, 832-834
8. Swerdlow, A. J. and Jones, M. E. (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study J. Natl. Cancer Inst. 97, 375-384
9. Han, X. L. and Liehr, J. G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen Cancer Res. 52, 1360-1363
10. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite Carcinogenesis 15, 2087-2094
11. Kim, S. Y., Suzuki, N., Laxmi, Y. R., and Shibutani, S. (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer Drug Metab. Rev. 36, 199-218
12. Marques, M. M. and Beland, F. A. (1997) Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide Carcinogenesis 18, 1949-1954
13. Beland, F. A., McDaniel, L. P., and Marques, M. M. (1999) Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo Carcinogenesis 20, 471-477
14. Bolton, J. L., Yu, L., and Thatcher, G. R. (2004) Quinoids formed from estrogens and antiestrogens Methods Enzymol. 378, 110-123
15. Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., and Clemens, J. A. (1984) Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[ b ]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[ b ]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity J. Med. Chem. 27, 1057-1066
16. Clemett, D. and Spencer, C. M. (2000) Raloxifene: A review of its use in postmenopausal osteoporosis Drugs 60, 379-411
17. DeMichele, A., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., Schinnar, R., Burgh, D., Berlin, M., Rubin, S. C., Rebbeck, T. R., and Strom, B. L. (2008) Impact of raloxifene or tamoxifen use on endometrial cancer risk: A population-based case-control study J. Clin. Oncol. 26, 4151-4159
18. Vogel, V. G. (2009) The NSABP study of tamoxifen and raloxifene (STAR) trial Expert Rev. Anticancer Ther. 9, 51-60
19. Wickerham, D. L., Costantino, J. P., Vogel, V. G., Cronin, W. M., Cecchini, R. S., Ford, L. G., and Wolmark, N. (2009) The use of tamoxifen and raloxifene for the prevention of breast cancer Recent Results Cancer Res. 181, 113-119
20. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2004) Oxidation of raloxifene to quinoids: Potential toxic pathways via a diquinone methide and o-quinones Chem. Res. Toxicol. 17, 879-888
21. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation Chem. Res. Toxicol. 15, 907-914
22. Liu, J., Li, Q., Yang, X., van Breemen, R. B., Bolton, J. L., and Thatcher, G. R. (2005) Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: Raloxifene proof-of-principle study Chem. Res. Toxicol. 18, 1485-1496
23. Baer, B. R., Wienkers, L. C., and Rock, D. A. (2007) Time-dependent inactivation of P450 3A4 by raloxifene: Identification of Cys239 as the site of apoprotein alkylation Chem. Res. Toxicol. 20, 954-964
24. Pearson, J. T., Wahlstrom, J. L., Dickmann, L. J., Kumar, S., Halpert, J. R., Wienkers, L. C., Foti, R. S., and Rock, D. A. (2007) Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: A key role for C239 in quenching reactive intermediates Chem. Res. Toxicol. 20, 1778-1786
25. Yukinaga, H., Takami, T., Shioyama, S. H., Tozuka, Z., Masumoto, H., Okazaki, O., and Sudo, K. (2007) Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry Chem. Res. Toxicol. 20, 1373-1378
26. Liu, H., Qin, Z., Thatcher, G. R., and Bolton, J. L. (2007) Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene Chem. Res. Toxicol. 20, 1676-1684
27. Kemp, D. C., Fan, P. W., and Stevens, J. C. (2002) Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance Drug Metab. Dispos. 30, 694-700
28. Obach, R. S., Kalgutkar, A. S., Soglia, J. R., and Zhao, S. X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose Chem. Res. Toxicol. 21, 1814-1822
29. Liu, H., Liu, J., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2005) Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-Fluoro substitution prevents quinoid formation Chem. Res. Toxicol. 18, 162-173
30. Domanski, T. L., Liu, J., Harlow, G. R., and Halpert, J. R. (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and alpha-naphthoflavone stimulation Arch. Biochem. Biophys. 350, 223-232
31. Shen, A. L., Porter, T. D., Wilson, T. E., and Kasper, C. B. (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis J. Biol. Chem. 264, 7584-7589
32. Brauman, J. I. (1966) Least squares analysis and simplification of multi-isotope mass spectra Anal. Chem. 38, 607-610
33. Korzekwa, K., Howald, W. N., and Trager, W. F. (1990) The use of Brauman's least squares approach for the quantification of deuterated chlorophenols Biomed. Environ. Mass Spectrom. 19, 211-217
34. Day, B. W., Skipper, P. L., Zaia, J., and Tannenbaum, S.R. (1991) Benzo[ a ]pyrene anti -diol epoxide covalently modifies human serum albumin carboxylate side chains and imidazole side chain of histidine(146) J. Am. Chem. Soc. 113, 8505-8509
35. Skipper, P. L., Naylor, S., Gan, L. S., Day, B. W., Pastorelli, R., and Tannenbaum, S. R. (1989) Origin of tetrahydrotetrols derived from human hemoglobin adducts of benzo[ a ]pyrene Chem. Res. Toxicol. 2, 280-281
36. Fishelovitch, D., Shaik, S., Wolfson, H. J., and Nussinov, R. (2009) Theoretical characterization of substrate access/exit channels in the human cytochrome P450 3A4 enzyme: Involvement of phenylalanine residues in the gating mechanism J. Phys. Chem. B 113, 13018-13025